Gut Liver. 2014;8(3):248-53.
Proton pump inhibitor use before percutaneous endoscopic gastrostomy is associated with adverse outcomes.
제1저자 임종필 · 교신저자 차재명
소속 (7)
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
- Department of Internal Medicine, Daegu Catholic University Medical Center, Catholic University of Daegu School of Medicine, Daegu, Korea.
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
BACKGROUND/AIMS Knowledge of the risk factors associated with adverse outcomes after percutaneous endoscopic gastrostomy (PEG) may be helpful for developing PEG recommendations. The purpose of this study was to identify the clinical risk factors associated with adverse clinical outcomes after PEG, especially regarding the use of proton pump inhibitors (PPIs).
METHODS We retrospectively reviewed the data from PEG patients at seven university hospitals between June 2006 and January 2012. All patients were followed up through February 2012 after PEG, and the clinical risk factors for adverse clinical outcomes after PEG were analyzed.
RESULTS Data from 1,021 PEG patients were analyzed. PPI users were more frequently included in the complication group than the noncomplication group (p=0.040). PEG-related complications (p=0.040) and mortality (p=0.003) were more frequent in the PPI group than in the control group. In the subgroup analysis of complicated PEG cases, infectious complications were more frequently found in the PPI group than in the control group (35.8% vs 27.8%). After adjustment for multiple possible confounding factors, PPI users (odds ratio, 1.531; 95% confidence interval, 1.017 to 2.305) and diabetic patients had increased mortality after PEG.
CONCLUSIONS PPI use may be associated with adverse outcomes in patients with PEG; however, further prospective studies investigating this issue are warranted.
Keywords
ComplicationMortalityPercutaneous endoscopic gastrostomyProton pump inhibitorsRisk factors
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
그 밖의 정보
- 출판 형태
- Journal Article
- 저널
- Gut and liver · eISSN 2005-1212
- MeSH
- Aged · Case-Control Studies · Enteral Nutrition / adverse effects / mortality · Female · Gastroscopy / adverse effects / mortality · Gastrostomy / adverse effects / mortality · Humans · Male · Prognosis · Proton Pump Inhibitors / adverse effects · Republic of Korea · Retrospective Studies · Risk Factors
- Substances
- Proton Pump Inhibitors
- 참고문헌
- 36편